Clinical Trial

Magnetic Resonance (MR) Imaging With Hyperpolarized Bicarbonate (13C) to Measure Tissue pH in Prostate Cancer

Active, Not Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This is a single site, prospective pilot study to determine the feasibility and safety of the administration of HP 13C bicarbonate in 10 patients with prostate cancer to determine potential hydrogen (pH) values in surrounding tissue. The proposed study will evaluate pre-surgical participants with histologically confirmed localized prostate cancer who receive infusion of hyperpolarized 13C injection prior to MR imaging with endorectal coil.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-05-01; most recent amendment 2026-04-28.
Status change: Recruiting → Active, Not Recruiting 2025-05-05
Status change: Not Yet Recruiting → Recruiting 2023-07-31
Trial Details
NCT Number NCT05851365
Lead Sponsor Robert Flavell, MD, PhD
Collaborators: U.S. Army Medical Research Acquisition Activity, Bristol-Myers Squibb
Conditions Prostate Cancer, Localized Prostate Carcinoma
Enrollment 1 participants
Start Date 2023-07-06
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-04